Alun is a Director in KPMG’s Government Incentives practice in Melbourne. He has over 20 years’ experience in assisting clients access government support for innovation and R&D activities and has worked closely with many biotech, medtech and pharmaceutical companies over that time.

Alun is a member of KPMG’s national Health & Life Sciences practice and has a Master’s Degree in Physics from the University of Melbourne.

As a member of the BioMelbourne Network Board, Alun plays a key role in supporting the executive team respond to government’s formulation of new research funding policy and review of programs such as the R&D Tax Incentive.

Ms Sue MacLeman, Managing Director and Chief Executive Officer, MTPConnect

Ms MacLeman has more than 25 years’ experience as a pharmaceutical, biotechnology and medical technology executive with roles in corporate, medical, commercial and business development at Schering-Plough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast Ltd.

Sue has also served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently a non-executive director at Reproductive Health Sciences Ltd. and Oventus Medical Ltd.

Dr Matt Harris, PhD, MBA, Managing Director, Clarity Pharmaceuticals

Matt brings experience in biotechnology, pharmaceuticals, regulatory requirements, academic research and investment to Clarity.  Matt has held leading managerial positions in Australian industry including CEO of Gateway Capital, an investment firm operating in the life science sector, CEO of an ASX listed medical device company and CEO of a start-up biopharmaceutical company.  In addition, Matt has worked closely with government and regulatory agencies, as a former member of a drug evaluation committee within the Australian Therapeutics Goods Administration (TGA).  Matt is currently the principal and co-founder of TM Ventures.

Matt McNamara, BioMedical Translation Fund, Bioscience Managers

Matt is responsible for deal flow management and evaluation, leading all investment recommendations and due diligence. He has over 25 years experience in the healthcare & medical sciences sector. After initially being a Molecular Biology Research Assistant, Matt spent 11 years in Sales & Marketing, and General Management with Merck & Co. and Johnson and Johnson Medical Pty Ltd respectively. He has served as SVP Business Development for eBioinformatics Inc and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty Ltd.

Matt founded BioBridge Australia, a biotechnology commercialisation Advisory company, in 2004 and advised a number of private and public biotechnology/investment companies. Matt joined BioScience Managers in 2005 and has been Chief Investment Officer since 2008.

Matt is currently a Director of: BioScience Managers Ltd; Avita Medical Ltd (ASX.AVH);  Sea Dragon Ltd (NZX.SEA); SciCapital Pty Ltd; Rex Bionics Limited (NZ); Saluda Medical Pty Ltd.

Dr Carolyn O’Brien, Senior International Relations and Policy Officer, ATSE

Dr Carolyn O’Brien joined ATSE in October 2015 to lead its international engagement and strategy work. She brought to ATSE a wealth of experience in international relations and extensive international networks having worked in the International Office at Melbourne University for over ten years. Carolyn is currently part of the ATSE team working on the Global Connections Fund which connects researchers and SMEs, an element of the Government’s National Innovation and Science Agenda. Carolyn has a PhD in European Studies from Monash University.

Our final speaker will be announced shortly…